Key Highlights

  • Telix received a first US approval for Pixclara, a new brain-cancer imaging agent, in the September 2026 quarter.
  • A proposed Merger with ITM carries upfront consideration of US$1.65 billion on a cash-free, debt-free basis.
  • About US$1.25 billion of the upfront consideration would be paid to ITM shareholders in Telix shares.
  • A further contingent payment of up to US$700 million is linked to ITM-11 milestones.

What does Telix Pharmaceuticals (ASX:TLX) look like after a quarter that combined a first US approval for a new brain-cancer imaging agent with a proposed US$1.65 billion merger? On the evidence of the company's third-quarter 2026 release, dated 20 October 2026, it is a Business with Revenue of roughly US$245 million a quarter, a growing commercial prostate-imaging Franchise and a pipeline that is increasingly moving from imaging into therapy. The merger with ITM, if shareholders approve it, would push that transition further and faster. The period-specific figures provide context for the company’s operating performance and execution priorities.

The central development: ITM and a first glioma approval

Two items stand out in the 20 October release. The first is the proposed merger with ITM, a radiopharmaceutical group focused on therapy. A further contingent payment of up to US$700 million is linked to regulatory and commercial milestones for ITM-11. Closing requires Telix Shareholder approval, and a general meeting is scheduled for 1 December 2026 (AEDT).

The second is regulatory. According to the company, the US Food and Drug Administration has approved Pixclara (floretyrosine F 18), described as the first approved imaging agent for glioma in the United States, and first commercial doses were administered in September 2026. This matters because it adds a third commercial imaging product to a portfolio that has so far been dominated by prostate-cancer imaging.

These are company statements. Value creation depends on shareholder approval, ITM-11 outcomes and integration, none of which is known today.

Business model and revenue drivers

Telix operates in theranostics: it uses a radioactive imaging agent to locate a cancer target and, in some programmes, a matching radioactive therapy to treat it. Revenue comes from two main areas. Precision Medicine covers commercial imaging products, principally Illuccix and Gozellix for prostate cancer. Telix Manufacturing Solutions, or TMS, supplies radioisotopes, equipment and related services to third parties.

Reported third-quarter 2026 revenue was US$245 million, up 19% on the September 2025 quarter (US$206 million) and down 1% on the June 2026 quarter (US$247 million). Precision Medicine contributed US$201 million, up 30% year on year, while third-party TMS revenue was US$44 million, down 6% year on year. US dose volumes rose 1% on the prior quarter, which management attributed to expected summer seasonality, and it said September sales produced a higher exit rate. These are unaudited figures.

Guidance and recent results

For FY2026, Telix guided to revenue of US$950 million to US$970 million, tracking toward the upper end, with a further US$40 million of other income. Total revenue and other income is expected to exceed US$1 billion. Management expects Precision Medicine revenue growth above 25% for the year, and narrowed Research and Development spending guidance to US$240 million to US$260 million from US$230 million to US$270 million. Guidance is the company's expectation, not a result, and could be revised.

The release did not disclose a cash balance, so Liquidity is not assessed here. An earlier company update, summarised by, also referred to US$600 million of convertible bonds due 2031 and a US$40 million non-refundable payment from a collaboration with Regeneron; readers should confirm both against the original filings.

Pipeline and regulatory calendar

The pipeline is broad, which is both its attraction and its risk. Items reported on 20 October include:

Zircaix (kidney cancer imaging): Telix received a corrected Complete Response Letter from the FDA and is finalising a Biologics License Application resubmission, addressing remaining third-party manufacturing observations. The company calls resubmission a top priority for 2026 and expects it in the near term.

Illuccix in Japan: Phase 3 enrolment is complete, a conditional approval is under review by the regulator, and a New Drug Application is being prepared.

Pixlumi (European Brand for floretyrosine F 18): the Marketing Authorisation Application remains under review.

Therapeutics: ProstACT Global Phase 3 (TLX591) is enrolling in seven countries outside the US while an amendment is finalised to proceed in the US. OPTIMAL-PSMA (TLX597) has enrolled 120 patients with data expected in the first half of 2027. LUTEON (TLX250, clear cell renal cell carcinoma) is enrolling, and the IPAX programme (TLX101, glioblastoma) reported that a newly diagnosed-patient study met its primary endpoint on safety dosing.

The Zircaix history shows manufacturing observations can delay a product.

Sector and competitive position

Radiopharmaceuticals have attracted heavy Investment from large pharmaceutical companies in recent years, and competition for isotope supply, manufacturing capacity and clinical sites is rising. Telix's response is vertical integration. Its TMS division reports contracts for 50 QUANTM irradiation systems through ARTMS, operates radiopharmacy sites, and has a collaboration with Ekalia, a joint venture of IBA and Framatome, to establish US production of astatine-211, an alpha-emitting isotope. Controlling Supply can help where isotopes decay quickly, but adds Capital intensity.

Material risks and what to watch

Shareholder vote: the ITM merger needs Telix shareholder approval, and the outcome on 1 December 2026 is uncertain.

Dilution: issuing roughly US$1.25 billion of equity, plus contingent payments, would affect existing holders.

Regulatory outcomes: Zircaix resubmission, the Pixlumi decision in Europe, Japanese reviews and the BiPASS filing all carry approval risk.

Clinical risk: therapeutic programmes can Fail in pivotal studies even after promising early data.

Manufacturing, competition and reimbursement: isotope logistics are complex and US prostate imaging pricing could pressure the main revenue stream.

Upcoming dated items are the 1 December 2026 general meeting, the Zircaix resubmission (described as near term, no date given) and the OPTIMAL-PSMA data in the first half of 2027.

Bottom line

The facts are documented; the outcomes remain uncertain.